Business Wire

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Share

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.

The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.

“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”

“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”

About YH001
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).

About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.

About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.

About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Biocytogen
Drug Assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF to Webcast 2022 Investor Day Presentations on December 729.11.2022 00:15:00 EET | Press release

IFF (NYSE:IFF) today announced that it will webcast its 2022 Investor Day presentation on Wednesday, Dec. 7, 2022, beginning at 1:00 p.m. ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.b

Megaport Adds Cloud and Networking Sales Veteran Jeff Tworek to the Executive Team as Chief Revenue Officer29.11.2022 00:00:00 EET | Press release

Megaport​ (ASX: MP1), a leading global Network as a Service (NaaS) provider, announced today the addition of Jeff Tworek to the executive team as Chief Revenue Officer. Tworek will be responsible for overall revenue generation and will manage all aspects of Megaport’s global sales organisation. Mr Tworek brings more than 30 years of cloud and networking industry experience operating commercial business units within billion-dollar companies, including nearly 20 years at Akamai Technologies, to Megaport. Prior to joining the Company, Mr Tworek held the CRO position at Contrast Security, where he helped the company scale its teams, bring in key leadership, and prepare the company for growth. He brings a wealth of high growth and expansion-related expertise from his time spent at both start-ups and large, established organizations. “We are delighted to welcome Jeff to the team,” said Vincent English, Chief Executive Officer, Megaport. “Jeff’s experience with leading and transforming global

AGCO Agriculture Foundation Donates to UK's Biggest Charity Fighting Hunger and Tackling Food Waste28.11.2022 22:52:00 EET | Press release

The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a USD 300,000 grant to FareShare to ensure surplus food reaches vulnerable communities in the United Kingdom while tackling food waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005695/en/ AAF grant to FareShare to secure 475 tonnes of surplus food. (Photo: Business Wire) The two-year partnership is expected to help FareShare secure 475 tonnes of surplus food and redistribute more than one million meals. The project will assist in growing the award-winning Surplus with Purpose Fund, which covers the cost for farmers to harvest and divert food that would have otherwise been wasted. The Intergovernmental Panel on Climate Change estimates that food waste contributes between 8 and 10 percent of global greenhouse gas emissions, so tackling food waste is

Quantfury Introduces Fractional Trading Mode for Stocks, ETFs and Commodities28.11.2022 21:00:00 EET | Press release

Quantfury Trading Limited (“Quantfury”), a global brokerage firm that delivers commission-free trading and investing at real-time spot prices of global and crypto exchanges, today announced the launch of fractional trading mode with more than 1500+ stocks, ETFs and commodity futures contracts available to trade on the Quantfury platform. Quantfurians can now buy and sell fractional shares of all stocks, ETFs and commodity futures contracts at their real-time US and European exchanges spot prices with zero commissions and borrowing fees, providing improved trading and investment experience. “Quantfury is advancing its unmatched trading and investing conditions further by making it even more affordable to Quantfurians out there,” said Daniel Muvdi, Quantfury’s Head of Markets. “Fractional trading mode opens up more trading opportunities to the Quantfury global audience of more than 400,000 Quantfurians.” Fractional trading mode is available on all Quantfury trading platforms immediately,

The 4th World Science and Technology Development Forum Held in Chengdu28.11.2022 19:06:00 EET | Press release

The 4th World Science and Technology Development Forum with the theme “Openness, Trust and Cooperation” kicked off in Chengdu on November 27, 2022, which was attended by more than 300 top experts and scholars, representatives of international organizations, and entrepreneurs, from more than 20 countries and regions, including 7 Nobel laureates and more than 60 academicians home and abroad. Together, they discussed technological innovation and sustainable development in key fields such as basic science, climate change, digital economy, and green innovation, and proposed technological innovation solutions to address the challenges of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005539/en/ The 4th World Science and Technology Development Forum Held in Chengdu (Photo: Business Wire) The world today is facing many challenges, such as the COVID-19 pandemic, energy security, food security, climate change, poverty, an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom